Epidermolysis Bullosa Acquisita: Symptoms, Diagnosis, and Treatment

Blisters that develop after a small bump or rub can sometimes be a sign of epidermolysis bullosa acquisita (EBA), a rare autoimmune skin disease. The name can be confusing: EBA is acquired during life and is not the same as inherited epidermolysis bullosa. It may cause fragile skin, slow-healing sores, milia, scars, or—in some people—blisters affecting the mouth, eyes, or other mucosal surfaces.

EBA can resemble several more common blistering conditions, so diagnosis often requires a skin biopsy and specialized immunologic tests. This guide explains the main patterns, how clinicians distinguish EBA from inherited skin fragility and other diseases, and the kinds of treatment and wound care that may be considered.

What is epidermolysis bullosa acquisita?

Epidermolysis bullosa acquisita is an uncommon autoimmune blistering disease affecting the skin and sometimes mucous membranes. In EBA, the immune system makes antibodies against type VII collagen, a structural protein that helps form anchoring fibrils. These fibrils secure the epidermis, the outer skin layer, to deeper tissue. When this attachment is disrupted, skin can separate after relatively minor friction or inflammation.

EBA is not inherited and not contagious. It is not caused by a mutation passed from a parent, and it cannot spread through touch. The word “acquisita” means acquired. Inherited epidermolysis bullosa (EB) is a different group of genetic conditions that usually becomes apparent in infancy or childhood. EBA is generally diagnosed later in life, although children can rarely develop it.

There is more than one clinical pattern. The classic mechanobullous form tends to cause skin fragility and blisters over areas exposed to pressure or repeated friction, such as the backs of the hands, elbows, knees, feet, and ankles. An inflammatory form can look more like bullous pemphigoid, with widespread itchy, inflamed blisters. A person may show features of more than one pattern.

Some people have involvement of the mouth, eyes, nose, throat, esophagus, or genital mucosa. These sites matter because repeated inflammation can cause adhesions or scarring that affect function. EBA can also occur alongside inflammatory bowel disease, particularly Crohn disease. This association does not mean everyone with EBA has bowel disease, but persistent digestive symptoms are worth discussing with a clinician.

Symptoms and clinical patterns

Classic mechanobullous pattern

The classic form causes tense blisters, erosions, or blood-filled blisters after minor trauma. Lesions often appear over hands, feet, elbows, knees, ankles, and other bony or friction-prone areas. A patient may notice a blister after carrying bags, using tools, walking in stiff shoes, or bumping a surface—activities that would not usually injure healthy skin.

When blisters heal, they may leave thin scars, darker or lighter patches, and small firm white cysts called milia. Repeated inflammation around the nails can lead to nail ridging, thickening, loss, or distortion. Scarring on the hands or feet can interfere with movement, gripping, walking, or wearing shoes.

Inflammatory pattern

Some people develop widespread red or itchy plaques with tense blisters. This can resemble bullous pemphigoid, linear IgA bullous dermatosis, or other subepidermal blistering conditions. Inflammatory EBA may occur on the trunk, limbs, or skin folds rather than only at trauma-prone sites. Itching and inflammation may be more noticeable than skin fragility.

Mucosal symptoms

The mouth may develop blisters, erosions, gum soreness, or painful areas that make eating and brushing uncomfortable. Eye involvement can cause irritation, redness, light sensitivity, or changes that need assessment by an ophthalmologist. Nasal, throat, esophageal, or genital lesions can cause crusting, hoarseness, swallowing pain, narrowing, urinary symptoms, or scarring.

Not every person with EBA develops mucosal disease. But new eye symptoms, trouble swallowing, breathing changes, or persistent oral or genital sores should be raised promptly with the care team. The absence of a blister at the appointment does not rule out a problem; fragile lesions can break quickly and leave only an erosion.

Symptoms can fluctuate over time. A new blister may appear while another site is healing, and scars or pigment changes can persist after active inflammation improves. Photographing the skin may help show how lesions change, but an image cannot establish the diagnosis.

How EBA is diagnosed

Diagnosis often takes time because EBA is rare and can resemble inherited skin fragility, other autoimmune blistering diseases, lupus-related blisters, porphyria cutanea tarda, or pseudoporphyria. A dermatologist may ask when symptoms began, which sites are affected, whether minor friction causes blisters, how lesions heal, and whether there are mouth, eye, bowel, or joint symptoms.

Skin biopsy and immunofluorescence

A biopsy from a fresh blister or its edge may show a split below the epidermis. The inflammation can be sparse or neutrophil-rich. A second sample of nearby, intact skin is often collected for direct immunofluorescence (DIF), which detects immune deposits at the basement membrane zone. The samples should be sent in the correct transport medium because routine histology and DIF require different handling.

DIF may show a linear band of IgG and complement C3 along the basement membrane. A characteristic u-serrated pattern can support EBA when interpreted by a trained laboratory. Other tests can include indirect immunofluorescence on salt-split skin, which may show antibodies binding to the dermal “floor,” and blood tests such as ELISA that detect antibodies to type VII collagen.

No single test is perfect. Some people have negative blood tests, and a biopsy result may need expert interpretation. Clinicians combine the physical pattern with biopsy, DIF, salt-split testing, collagen VII assays, and sometimes specialist techniques such as immunoelectron microscopy or fluorescence overlay antigen mapping.

Distinguishing EBA from inherited epidermolysis bullosa

Inherited EB is caused by genetic changes affecting proteins that hold skin layers together. It often begins in infancy or childhood and may have a family history, though family history can be absent. EBA is an autoimmune disease that is usually acquired in adulthood and is associated with antibodies against type VII collagen. Clinical timing alone is not enough to separate them; genetic testing, immunologic testing, and skin studies may be used as appropriate.

Other diagnoses include bullous pemphigoid, mucous membrane pemphigoid, linear IgA disease, dermatitis herpetiformis, bullous systemic lupus erythematosus, porphyria cutanea tarda, and drug-induced skin fragility. Some produce blisters at similar tissue depths but differ in their immune targets or laboratory pattern. Correct classification guides treatment.

Preparing for a specialist visit

Before an appointment, note when the first lesion appeared, which areas are affected, whether blisters follow friction, and how long wounds take to heal. If a blister forms after an unusual activity, record the event without intentionally trying to reproduce it. Dated photos of the skin before and after lesions break can help show changes between visits; use secure storage and share them only with the care team.

Bring a complete list of prescription medicines, over-the-counter products, supplements, and recent dose changes. Mention whether symptoms began in infancy or adulthood, whether relatives had similar skin fragility, and whether there are mouth, eye, genital, or bowel symptoms. These details help clinicians distinguish acquired EBA from inherited epidermolysis bullosa, other autoimmune blistering diseases, and porphyria-related conditions.

Ask whether the evaluation needs separate biopsy samples for routine histology and direct immunofluorescence, and how to prepare the skin before sampling. Tell the clinician if a wound dressing sticks, if lesions are infected, or if you are taking anti-inflammatory or immune-suppressing medicines. A negative blood test may not exclude EBA, so ask how the full set of results will be interpreted and whether repeat or specialized testing is needed.

Treatment and skin protection

There is no one treatment that works for every person with EBA, and evidence is limited because the disease is rare. The care plan depends on the clinical pattern, how widespread the disease is, whether mucous membranes are involved, previous response, age, and other health conditions. A dermatologist with experience in autoimmune blistering diseases may coordinate care with ophthalmology, gastroenterology, oral medicine, wound care, or other specialties.

Reduce friction and protect open skin

For fragile skin, practical steps may reduce new trauma: wear soft clothing, use padded footwear, avoid rough seams, protect hands during activities, and minimize adhesive tape on affected areas. A clinician or wound-care nurse can recommend non-adherent dressings and gentle cleansing for open erosions. Do not lance blisters or use caustic antiseptics unless a clinician specifically instructs you.

Wound care aims to protect the blister roof when possible, manage drainage, reduce pain, and watch for infection. A dressing should not stick to the wound when removed. The right material and change schedule depend on location, fluid, infection risk, and the person's mobility. Ask for a plan if wounds are recurrent, difficult to dress, or interfering with daily activities.

Blisters can become infected. Increasing tenderness, warmth, swelling, spreading redness, pus, odor, fever, or feeling unwell needs medical review. A swab may be taken if infection is suspected. Antibiotics are used when clinically appropriate; they do not treat the autoimmune cause of EBA.

Medicines that may be considered

Specialists may use anti-inflammatory or immune-modulating medicines, such as corticosteroids, dapsone, colchicine, immunosuppressants, rituximab, or intravenous immunoglobulin. Other options may be considered in selected cases. The medicine choice depends on the person's disease pattern, site, severity, comorbidities, laboratory findings, and treatment history.

These treatments have important risks. For example, systemic corticosteroids can affect blood sugar, blood pressure, bone health, and infection risk; other immune-modulating medicines may require blood counts, liver or kidney tests, screening for infections, or vaccination planning. Dapsone can affect blood cells and oxygen carrying, especially in people with G6PD deficiency. A prescriber should explain required tests and symptoms to report before treatment starts.

There is no established universal dosing schedule or guaranteed rapid response. Some people need a combination of wound care and systemic therapy over an extended period, while others improve with a different approach. Never start, stop, or change prescription treatment without the clinician who manages the disease.

Protect mucous membranes and function

Oral lesions may need local treatment and guidance from a dentist or oral medicine specialist. Eye involvement calls for an ophthalmologist because scarring can affect vision. Hoarseness, painful swallowing, or breathing changes may require ENT evaluation; difficulty swallowing may require further tests for esophageal disease. Genital lesions can need gynecology, urology, or dermatology support.

If you also have persistent diarrhea, abdominal pain, blood in the stool, or unexplained weight loss, mention it to your clinician. EBA can be associated with inflammatory bowel disease, and digestive symptoms deserve appropriate evaluation rather than being attributed automatically to the skin condition.

Outlook and follow-up

EBA can be chronic and may relapse. Available evidence suggests that life expectancy is generally normal, but scarring, infection, and mucosal complications can cause substantial disability. The course varies: some people gain control, while others continue to develop blisters or erosions despite treatment. Mechanobullous disease can be difficult to control, and mucosal involvement may carry additional risk. Follow-up should track not only the number of blisters but also scars, healing, infection, hand or foot function, and symptoms at the mouth, eyes, throat, and genitals.

Patients taking systemic treatment may need regular laboratory monitoring and screening for adverse effects. Keep appointments even during a quiet period, and tell clinicians if a new medicine is started by another provider. If disease is not improving or treatment causes side effects, the plan may need adjustment rather than simply continuing unchanged.

It can help to keep a brief record of new lesions, likely friction events, medicine changes, pain, wound status, and mucosal symptoms. Photos may be useful if taken consistently, but store them privately and do not postpone care for a serious symptom. Ask the clinic which symptoms should prompt a same-day call and which require emergency care.

When to seek medical care

Arrange a medical assessment for recurrent blisters after minor friction, slow-healing sores, scars with tiny white cysts, nail changes, or blistering accompanied by mouth or eye symptoms. Bring a list of prescription medicines, over-the-counter products, supplements, and recent changes. Mention bowel symptoms such as persistent abdominal pain, diarrhea, or blood in the stool.

Seek prompt medical advice for rapidly spreading blisters, increasing pain, fever, pus, or spreading redness. New eye pain, light sensitivity, blurred vision, mouth sores that prevent drinking, painful swallowing, persistent hoarseness, or genital erosions should be assessed promptly. Call emergency services for breathing difficulty or severe illness.

Useful questions for a dermatologist include: “Could this be an acquired autoimmune blistering disease rather than inherited EB?” “Do I need a biopsy for direct immunofluorescence?” “Can a collagen VII test help?” “How should I protect open areas?” and “What symptoms mean I need urgent care?”

Frequently asked questions

References and further reading

• DermNet. Epidermolysis bullosa acquisita: clinical features, diagnosis, and treatment. Reviewed 2026.
• International Bullous Diseases Group. Consensus on diagnostic criteria for epidermolysis bullosa acquisita. 2017.
• Epidermolysis Bullosa Acquisita: The 2019 Update. Frontiers in Medicine.
• Epidermolysis Bullosa Acquisita—Current and Emerging Treatments. 2023.
• Epidermolysis bullosa acquisita: clinical features, diagnosis, and treatment review. Anais Brasileiros de Dermatologia. 2022.
• Brazilian Society of Dermatology. Consensus on treatment of autoimmune bullous dermatoses, including epidermolysis bullosa acquisita. 2019.

Medical information notice: This article is for general education and is not a diagnosis or individualized treatment plan. New, spreading, painful, or infected blisters need clinical assessment. Seek urgent care for eye symptoms, swallowing difficulty, or breathing changes.